The Sledgehammer and the SEP
Explains India’s 2025 pro-enforcement shift in SEP litigation, covering FRAND disputes, unwilling licensee doctrine, interim deposits, and CCI jurisdiction limits.
INTERPRETING SEMAGLUTIDE: A CASE COMMENTARY ON NOVO NORDISK v. DR. REDDY’S
Semaglutide patent dispute India examines genus–species patent doctrine, evergreening pharmaceutical patents India and Section 64 Patents Act obviousness principles.
WOMEN INVENTORS AND INDIA’S PATENT ECOSYSTEM: READING GENDER INTO INNOVATION POLICY
Women inventors in India’s patent ecosystem highlight the need for gender-responsive innovation policy. Learn how women inventors in India’s patent ecosystem face structural barriers and why inclusive patent frameworks are essential for equitable participation, stronger research output and sustainable innovation growth.
SCENT WITHOUT LEGAL SHIELD
Why are scent without legal shield?
Gaps in IP laws leave fragrances vulnerable to imitation and unprotected.
PHARMA PATENT CLASH REDEFINES ACCESS
Pharma Patent Clash Redefines Access: Landmark Cipla v. Roche case reshaped India’s patent law, balancing innovation with public health.
PATENT COOPERATION TREATY IN INDIA
Explore how the Patent Cooperation Treaty has influenced Indian patent law, global filing, innovation access, and public health balance.
INDIA REJECTS NOVARTIS PATENT BID
The Novartis patent bid was rejected in India, setting a landmark precedent in balancing innovation and public health access.
ALICE SOFTWARE PATENTS RULING
The Alice software patents case redefined eligibility, creating lasting uncertainty in tech and legal innovation.
ACTAVIS V. ELI LILLY: UK PATENT LAW REDEFINED
Explore how Actavis v Eli Lilly (2017) reshaped UK patent law with the revival of the doctrine of equivalents and EPC alignment.
MAYO V PROMETHEUS: PATENT ELIGIBILITY EXPLAINED
Explore the landmark Mayo v Prometheus case clarifying patent eligibility of natural laws in medical diagnostics under US law.